Cargando…
Persistence and Compliance with Pazopanib in Patients with Advanced Renal Cell Carcinoma Within a U.S. Administrative Claims Database
BACKGROUND: Pazopanib is an oral tyrosine kinase inhibitor with demonstrated efficacy and tolerability in patients with advanced renal cell carcinoma (RCC). OBJECTIVES: To examine pazopanib persistence and compliance (adherence) and other drug utilization patterns in both treatment-naïve (first-line...
Autores principales: | Hackshaw, Michelle D., Nagar, Saurabh P., Parks, Daniel C., Miller, Lesley-Ann N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438225/ https://www.ncbi.nlm.nih.gov/pubmed/24856598 http://dx.doi.org/10.18553/jmcp.2014.20.6.603 |
Ejemplares similares
-
Identification of pregnancies and infants within a US commercial healthcare administrative claims database
por: Bertoia, Monica L., et al.
Publicado: (2022) -
Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database
por: Fan, Tao, et al.
Publicado: (2013) -
Labeling compliance and online claims for Ayurvedic herbal supplements on the U.S. market associated with the purported treatment of COVID-19
por: Jordan, Chevon R., et al.
Publicado: (2023) -
Real-World Prevalence of Type 2 Diabetes Remission in a U.S. Insured Population Using a Large Administrative Claims Database
por: Sheils, Natalie E., et al.
Publicado: (2023) -
Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database
por: Folkerts, Kerstin, et al.
Publicado: (2020)